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A cost too high to bear? 
Prophylaxis versus preemptive 
therapy to prevent post-
transplantation cytomegalovirus
MD Pescovitz1
Both prophylaxis and preemptive therapy are used to prevent the 
development of cytomegalovirus (CMV) disease after transplantation. 
Preemptive therapy exposes the least number of patients to costly 
and potentially toxic drugs. Prophylaxis is less labor intensive and 
requires less expensive monitoring. While the overall cost of the two 
modalities is similar, current literature suggests that prophylaxis has 
an advantage in avoiding secondary effects of CMV. Randomized 
comparative trials are imperative.
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Cytomegalovirus (CMV) has been and 
continues to be a major infectious dis-
ease following solid-organ transplan-
tation. Because of this, over the years 
diﬀerent modalities and diﬀerent drugs 
have been developed to prevent CMV. 
Although acyclovir and valacyclovir have 
been shown to be eﬀective, most centers 
rely on the various formulations of gan-
ciclovir. Winston et al. were the ﬁrst to 
demonstrate that ganciclovir, adminis-
tered intravenously, eﬀectively prevented 
CMV disease after liver transplantation.1 
This was followed by the report of Gane 
et al. demonstrating excellent results 
with the oral formulation of ganciclovir, 
again after liver transplantation.2 Dif-
ﬁculties with oral ganciclovir, primarily 
related to its poor bioavailability, were 
solved by the development and approval 
of valganciclovir.3 Through its active 
transport across the intestinal lumen, 
valganciclovir produces drug exposures 
in the blood similar to that achievable 
with the intravenous formulation.3,4 The 
eﬀectiveness of valganciclovir, providing 
results comparable to those with oral gan-
ciclovir for CMV prophylaxis, has now 
been established.5
Although ganciclovir and valganciclo-
vir are clearly eﬀective for the prevention 
of CMV disease, questions regarding 
how best to use these drugs still abound. 
Major areas of debate, particularly for val-
ganciclovir, include appropriate dosing,6 
duration of dosing,7 and the subject of 
the study reported by Dmitrienko et al.8 
(this issue), prophylaxis versus preemp-
tive treatment (Figure 1). As Dmitrienko 
et al.8 note, both ganciclovir and valgan-
ciclovir are expensive drugs, and their 
routine use may be associated with tox-
icity and selection of resistant strains of 
CMV. These concerns are the primary 
impetuses for preemptive treatment of 
CMV, where only patients demonstrat-
ing viremia receive therapy.
Clearly, the optimal design for answer-
ing which is the better approach, preemp-
tive treatment or prophylaxis, would be 
a prospective randomized, controlled 
trial.8 Although Dmitrienko et al.8 state 
that such a study has not been done, in 
fact, Khoury et al. did just that, albeit in a 
relatively small study that included both 
high- and low-risk transplants.9 Their 
conclusion was that “both prophylactic 
and preemptive approaches with valgan-
ciclovir were eﬀective in the management 
of CMV infection. Prophylaxis was more 
eﬀective in reducing the occurrence of 
CMV infection, but possibly less eﬀec-
tive in preventing symptomatic disease in 
high risk D+/R− patients.”9 Dmitrienko 
et al.8 found that a selective approach of 
prophylaxis for high risk and preemptive 
treatment for lower risk was somewhat 
less expensive than universal prophylaxis. 
This conclusion is somewhat at odds with 
that of Khoury et al., who found that “The 
cost of the two approaches was similar.”9 
Why is there this diﬀerence, and what can 
be learned from the comparison of the 
two studies?
First, and perhaps most important, is 
the viewpoint. Dmitrienko et al.8 state 
that their viewpoint was “that of a health 
provider within the Canadian health care 
system.” In actuality, it was that of their 
individual center within the Canadian 
system. How applicable are these ﬁndings 
to those outside their center or outside of 
Canada? For example, Dmitrienko et al.8 
matched donor and recipient for CMV 
serology within the deceased transplant 
pool, a practice uncommon in the United 
States. Perhaps more importantly, very 
few of their patients received a deplet-
ing antibody, as did almost all of those 
of Khoury et al.9 and about 50% of renal-
transplant recipients in the recent Sci-
entiﬁc Registry of Transplant Recipients 
report.10 With the increased risk of CMV 
following the use of depleting antibody, 
the pendulum may swing more to an 
advantage of prophylaxis.
Second, the use of the preemptive 
approach, though it saves on drug costs, 
is more labor- and diagnostic-intensive. 
Khoury et al. showed that, overall, the 
costs were similar, with those of the drug 
being oﬀset by those of monitoring.9 The 
study of Dmitrienko et al.8 is incomplete 
in this area, providing data on person-
nel costs but only for those who develop 
CMV infection or disease.
Third, some of the patients in the report 
of Dmitrienko et al.8 developed viremia 
while on oral prophylaxis. Their study 
included both oral ganciclovir and valgan-
ciclovir, whereas Khoury et al. studied only 
valganciclovir.9 As is noted by Dmitrienko 
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et al.8 and reported by Paya et al.,5 
valganciclovir was statistically more 
eﬀective in preventing CMV infection in 
patients on therapy. It is not clear what 
impact this variability would have had on 
the rates of CMV antigenemia and ulti-
mately the cost of the two approaches.
Both reports include the cost of moni-
toring, and, as noted, this is a highly vari-
able expense from center to center based 
on volume.9 Dmitrienko et al.8 found that 
monitoring was a poor predictor of CMV 
disease. This should not be a surprise, as 
the patients received antiviral therapy as 
soon as an antigenemia level over four 
cells was found, thus preventing progres-
sion to disease. The study by Paya et al. 
demonstrated that with the very low rate 
of viremia, there would be no advantage 
to monitoring while on prophylaxis.5 
More importantly, monitoring after ces-
sation of prophylaxis was of no use in pre-
dicting who would develop CMV disease; 
this obviates the need for any monitoring 
in patients given prophylaxis.11
In deciding between a prophylaxis and 
a preemptive approach, an important 
question to be addressed is that of the 
indirect eﬀects of CMV. Increased rates 
of acute and chronic rejection, graft loss, 
opportunistic infections, increased rates 
of death and, most recently, increased 
rates of post-transplantation diabe-
tes have all been associated with CMV, 
often in an asymptomatic infection.8 
As Khoury et al.9 note, Sagedal et al. 
reported results from a prospective study, 
without prophylaxis (that is, preemptive), 
showing that even asymptomatic CMV 
antigenemia reduced graft survival and 
increased overall mortality.12 Similarly, 
Kalil et al., in a metaanalysis, showed 
that although preemptive therapy was 
similar to prophylaxis in preventing dis-
ease, only prophylaxis resulted in better 
patient survival.13
As a possible advantage to the preemp-
tive approach, allowance for an immu-
nizing event to occur in response to 
the viremia before application of the 
antiviral agent might prevent subse-
quent or late CMV. However, by study 
design, Dmitrienko et al.8 were using the 
preemptive approach only in the donor+/
recipient+ and donor–/recipient+ com-
binations, that is, in those subjects who 
had already been immunized through 
prior exposure. They do not provide any 
evidence that such an advantage would 
actually transpire.
Ultimately, the statement by Khoury 
et al. that “For now, the best approach 
to control of CMV after solid organ 
transplantation remains institution and 
resource dependent”9 may be the most 
unbiased assessment. The report by 
Dmitrienko et al.8 is the latest attempt 
to provide such an analysis of resources. 
Both reports agree that appropriately 
designed and powered studies comparing 
the two approaches are needed. The 
transplantation community should make 
such a study a high priority, particularly 
given the unlikelihood that such a study 
would be funded by industry.
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Figure 1 | What is the most cost-effective modality to prevent cytomegalovirus infection? 
The cytomegalovirus is an encapsulated DNA virus. Two primary modalities are used to prevent 
the development of cytomegalovirus disease after transplantation: prophylaxis and preemptive 
therapy. Cost consideration is a major driver in the choice between the two approaches. Figure 
adapted from ref. 14.
